Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.
The required activities of CD4(+) T cells and antibody against the virally encoded oncoprotein simian virus 40 (SV40) Tag have previously been demonstrated by our laboratory to be mediators in achieving antitumor responses and tumor protection through antibody-dependent cell-mediated cytotoxicity (ADCC). In this study, we further characterize the necessary immune cell components that lead to systemic tumor immunity within an experimental pulmonary metastatic model as the result of SV40 Tag immunization and antibody production. Immunized animals depleted of CD8(+) T cells at the onset of experimental tumor cell challenge developed lung tumor foci and had an overall decreased survival due to lung tumor burden, suggesting a role for CD8(+) T cells in the effector phase of the immune response. Lymphocytes and splenocytes harvested from SV40 Tag-immunized mice experimentally inoculated with tumor cells synthesized increased in vitro levels of the Th1 cytokine gamma interferon (IFN-gamma), as assessed by enzyme-linked immunosorbent assay (ELISA) and flow cytometry assays. CD8(+) T-cell activity was also heightened in SV40 Tag-immunized and tumor cell-challenged mice, based upon intracellular production of perforin, confirming the cytolytic properties of CD8(+) T cells against tumor cell challenge. Altogether, these data point to the role of recombinant SV40 Tag protein immunization in initiating a cytotoxic T-lymphocyte (CTL) response during tumor cell dissemination and growth. The downstream activity of CD8(+) T cells within this model is likely initiated from SV40 Tag-specific antibody mediating ADCC tumor cell destruction.
Lowe
Devin B
DB
Department of Microbiology, Texas Tech University Health Sciences Center, 3601 4th Street, MS 6591, Lubbock, TX 79430, USA.
Shearer
Michael H
MH
Jumper
Cynthia A
CA
Bright
Robert K
RK
Kennedy
Ronald C
RC
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000952:Antigens, Polyomavirus Transforming / Q000008:administration & dosage / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002461:Cell Line, Transformed; D056724:Immunity, Humoral; D007114:Immunization; D007668:Kidney / Q000166:cytology / Q000821:virology; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D008212:Lymphocyte Depletion; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D013539:Simian virus 40 / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic; D018417:Th1 Cells / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control
D000914:Antibodies, Viral; D000952:Antigens, Polyomavirus Transforming